Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512
This study is recruiting at 12 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- September 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 3
- Rocky Mountain Cancer Centers · Denver, CO
- United States Oncology Regulatory Affairs Corporate Office · Denver, CO
- US Oncology Research Investigational Products Center · Denver, CO
North Carolina · 1
- Duke University Medical Center · Durham, NC
Ohio · 1
- Oncology Hematology Care Incorporated · Cincinnati, OH
Pennsylvania · 2
- Thomas Jefferson University · Philadelphia, PA
- University of Pittsburgh Medical Center Hillman Cancer Center · Pittsburgh, PA
South Dakota · 1
- Sanford Oncology Clinic and Pharmacy · Sioux Falls, SD
Tennessee · 1
- Sarah Cannon Research Institute Oncology Partners · Nashville, TN
Texas · 2
- University of Texas MD Anderson Cancer Center · Houston, TX
- Next Oncology - Dallas · Irving, TX
Virginia · 1
- Virginia Oncology Associates - Hampton · Norfolk, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.